

CITATION REPORT

List of articles citing

Sildenafil in patients with cardiovascular disease

DOI: 10.1016/s0002-9149(02)03368-4
American Journal of Cardiology, 2003, 92, 26M-36M.

Source: <https://exaly.com/paper-pdf/35020180/citation-report.pdf>

Version: 2024-04-24

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
32	Overview of phosphodiesterase 5 inhibition in erectile dysfunction. <i>American Journal of Cardiology</i> , 2003 , 92, 9M-18M	3	160
31	Is there a need for novel antihypertensive therapies?. <i>Drug Discovery Today: Therapeutic Strategies</i> , 2004 , 1, 143-148		
30	Tadalafil: a long-acting PDE5 inhibitor for the management of erectile dysfunction. <i>Therapy: Open Access in Clinical Medicine</i> , 2004 , 1, 185-196		
29	Effects of sildenafil citrate on hepatic function and regeneration in normal and alcohol-fed rats. <i>Liver International</i> , 2005 , 25, 913-9	7.9	8
28	The therapeutic dilemma: how to use short-acting PDE5 inhibitor drugs. <i>Journal of Developmental and Physical Disabilities</i> , 2005 , 28 Suppl 2, 69-73		2
27	Effect of sildenafil citrate on the cardiovascular system. <i>Brazilian Journal of Medical and Biological Research</i> , 2005 , 38, 1303-11	2.8	8
26	Erectile dysfunction is a signal of risk for cardiovascular disease: a primary care view. <i>Primary Care - Clinics in Office Practice</i> , 2005 , 32, 977-93, vii	2.2	5
25	Phosphodiesterase 5 inhibitors for erectile dysfunction. <i>Annals of Pharmacotherapy</i> , 2005 , 39, 1286-95	2.9	61
24	Erectile Dysfunction in the Patients with Cardiovascular Disease. <i>Korean Journal of Urology</i> , 2006 , 47, 279		3
23	Short- and long-term effects of sildenafil on skin flap survival in rats. <i>Laryngoscope</i> , 2006 , 116, 522-8	3.6	50
22	Adverse effects of drug therapies on male and female sexual function. <i>World Journal of Urology</i> , 2006 , 24, 623-9	4	17
21	Side effects of using nitrates to treat angina. <i>Expert Opinion on Drug Safety</i> , 2006 , 5, 667-74	4.1	55
20	Hypertension, antihypertensive therapy, and erectile dysfunction. <i>Angiology</i> , 2006 , 57, 47-52	2.1	34
19	Effects of vardenafil on intraocular pressure and orbital hemodynamics. <i>Journal of Ocular Pharmacology and Therapeutics</i> , 2007 , 23, 275-9	2.6	4
18	Metabolic risk factors, endothelial dysfunction, and erectile dysfunction in men with diabetes. <i>American Journal of the Medical Sciences</i> , 2007 , 334, 466-80	2.2	14
17	Type 5 phosphodiesterase inhibitors in the treatment of erectile dysfunction and cardiovascular disease. <i>Cardiology in Review</i> , 2007 , 15, 76-86	3.2	52
16	Nitrate cessation profiles in men wishing to use sildenafil citrate. <i>Urology</i> , 2007 , 69, 946-9	1.6	2

15	Side effects of using nitrates to treat heart failure and the acute coronary syndromes, unstable angina and acute myocardial infarction. <i>Expert Opinion on Drug Safety</i> , 2007 , 6, 385-96	4.1	19
14	Diagnosis and management of erectile dysfunction in the primary care setting. <i>International Journal of Clinical Practice</i> , 2007 , 61, 1198-208	2.9	13
13	Current safety and tolerability issues in men with erectile dysfunction receiving PDE5 inhibitors. <i>International Journal of Clinical Practice</i> , 2007 , 61, 1547-54	2.9	20
12	Effect of treating erectile dysfunction on management of systolic hypertension. <i>American Journal of Cardiology</i> , 2007 , 100, 459-63	3	35
11	Blood pressure control and sildenafil--carrot stick or sword of Damocles?. <i>American Journal of Cardiology</i> , 2007 , 100, 552-3	3	2
10	Cilostazol, a specific PDE-3 inhibitor, ameliorates chronic ileitis via suppression of interaction of platelets with monocytes. <i>American Journal of Physiology - Renal Physiology</i> , 2009 , 297, G1077-84	5.1	10
9	Targeting cyclic nucleotide phosphodiesterase in the heart: therapeutic implications. <i>Journal of Cardiovascular Translational Research</i> , 2010 , 3, 507-15	3.3	38
8	Assessment of the acute effects of tadalafil on the cardiovascular system based on examination of serum oxidative status and paraoxonase activity in men with erectile dysfunction: a preliminary study. <i>International Journal of Impotence Research</i> , 2010 , 22, 115-9	2.3	15
7	Acute effect of phosphodiesterase type 5 inhibitor on serum oxidative status and prolidase activities in men with erectile dysfunction. <i>Clinics</i> , 2010 , 65, 1311-4	2.3	11
6	Medicinal Chemistry and Therapeutic Applications of the Gasotransmitters NO, CO, and H ₂ S and their Prodrugs. 2010 , 265-368		3
5	Cardiac arrest associated with sildenafil ingestion in a patient with an abnormal origin of the left coronary artery: case report. <i>BMC Cardiovascular Disorders</i> , 2011 , 11, 49	2.3	3
4	Indomethacin-induced small intestinal injury is ameliorated by cilostazol, a specific PDE-3 inhibitor. <i>Scandinavian Journal of Gastroenterology</i> , 2012 , 47, 993-1002	2.4	14
3	Selectivity of avanafil, a PDE5 inhibitor for the treatment of erectile dysfunction: implications for clinical safety and improved tolerability. <i>Journal of Sexual Medicine</i> , 2012 , 9, 2122-9	1.1	55
2	Tadalafil: a long-acting PDE5 inhibitor for the management of erectile dysfunction. <i>Therapy: Open Access in Clinical Medicine</i> , 2004 , 1, 185-196		
1	Post-coital death in chronic sildenafil abuser. <i>Journal of Geriatric Cardiology</i> , 2020 , 17, 169-172	1.7	